Discovery of (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide as an efficacious inhaled muscarinic acetylcholine receptor antagonist for the treatment of COPD

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 16, 2009, Pages 4560-4562

  Wan, Zehong ^a   Laine, Dramane I ^a   Yan, Hongxing ^a   Zhu, Chongjie ^a   Widdowson, Katherine L ^a   Buckley, Peter T ^a   Burman, Miriam ^a   Foley, James J ^a   Sarau, Henry M ^a   Schmidt, Dulcie B ^a   Webb, Edward F ^a   Belmonte, Kristen E ^a   Palovich, Michael ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Antagonist; COPD; Muscarinic; Tropane

Indexed keywords

(3 ENDO) 3 (2 CYANO 2,2 DIPHENYLETHYL) 8,8 DIMETHYL 8 AZONIABICYCLO[3.2.1]OCTANE BROMIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; SALMETEROL XINAFOATE; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SYNTHESIS; MOUSE; NONHUMAN;

ADMINISTRATION, INHALATION; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BIPHENYL COMPOUNDS; DRUG DISCOVERY; HUMANS; MICE; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RATS; RECEPTORS, MUSCARINIC; STRUCTURE-ACTIVITY RELATIONSHIP;

MURINAE;

EID: 67651124937     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.006     Document Type: Article

References (27)

1. Romain P. Prog. Respir. Res. 31 (2001) 11
2. European Respiratory Society, European Lung Federation, European Lung White book, 2003.
3. Barnes P.J., Shapiro S.D., and Pauwels R.A. Eur. Respir. J. 22 (2003) 672
4. Barnes P.J. Am. J. Respir. Crit. Care Med. 160 (1999) S72
5. Barnes P.J., and Stockley R.A. Eur. Repir. J. 25 (2005) 1084
6. Boyd G., Morice A.H., Pounsford J.C., Siebert M., Peslis N., and Crawford C. Eur. Respir. J. 10 (1997) 815
7. Norman P., Graul A., Rabasseda X., and Castaner J. Drugs Future 25 (2000) 693
8. Eglen R.M., Choppin A., and Watson N. Trend. Pharmacol. Sci. 22 (2001) 409
9. Wess J. Trend. Pharmacol. Sci. 24 (2003) 414
10. Gaulfield M.P., and Birdsall N.J.M. Pharmacol. Rev. 50 (1998) 279
11. Disse B. Life Sci. 68 (2001) 2557
12. Fryer A.D., and Jacoby D.B. Am. J. Respir. Crit. Care Med. 158 (1998) S154
13. Gosens R., Zaagsma J., Meurs H., and Halayko A.J. Respir. Res. 7 (2006) 1
14. Belmonte K.E. Proc. Am. Thorac. Soc. 2 (2005) 297
15. Zirkle C.L., Geissman T.A., Bloom M., Craig P.N., Gerns F.R., Indik Z.K., and Pavloff A.M. J. Org. Chem. 27 (1962) 1269
16. Zirkle C.L., Anderson E.L., Craig P.N., Gerns F.R., Indik Z.K., and Pavloff A.M. J. Med. Chem. 5 (1962) 341
17. Takahashi Y., Yoneda N., and Nagai H. Chem. Lett. 11 (1985) 1733
18. Miyachi H., Kiyota H., and Segawa M. Bioorg. Med. Chem. Lett. 9 (1999) 3003
19. Sagara Y., Sagara T., Uchiyama M., Otsuki S., Kimura T., Fujikawa T., Noguchi K., and Ohtake N. J. Med. Chem. 49 (2006) 5653
20. Ertl P., Pohde B., and Selzer P. J. Med. Chem. 43 (2000) 3714
21. Arunlakshana O., and Schild H.O. Br. J. Pharmacol. 14 (1959) 48
22. Schroeder K.S., and Neagle B.D. J. Biomol. Screening 1 (1996) 75
23. Sarau H.M., Ames R.S., Chambers J., Ellis C., Elshourbagy N., Foley J.J., Schmidt D.B., Muccitelli R.M., Jenkins O., Murdock P.R., Herrity N.C., Halsey W., Sathe G., Muir A.I., Nuthulaganti P., Dytko G.M., Buckley P.T., Wilson S., Bergsma D.J., and Hay D.W.P. Mol. Pharmacol. 56 (1999) 657
24. Jin J., Budzik B., Wang Y., Shi D., Wang F., Xie H., Wan Z., Zhu C., Foley J.J., Webb E.F., Berlanga M., Burman M., Sarau H.M., Morrow D.M., Moore M.L., Rivero R.A., Palovich M., Salmon M., Belmonte K.E., and Laine D.I. J. Med. Chem. 51 (2008) 5915
25. Tallarida R.J., Cowan A., and Adler M.W. Life Sci. 25 (1979) 637
26. Balb/C mice (n = 4) were treated with the compound intra-nasally (in) and then challenged after 5 h with 30 mg/ml methacholine (aerosolized, 2 min). The magnitude of bronchoconstriction was measured as Penh over the next 5 min using a standard Buxco plethysmography system. The data is expressed as a ratio of the Penh achieved with methacholine after drug was given to that achieved before drug was given. A ratio of 1.0 (dotted line) indicates that there was no change in the Penh in response to aerosolized methacholine (i.e., 0% inhibition), and a ratio of 0.0 means that there was no bronchoconstriction in response to methacholine challenge (i.e., 100% inh.).
27. Same as Ref. 25 except the mice were treated with the compound for 0.25-48 h before the challenging.